Prospective NIS to examine the effectiveness of TDC in patients with metastatic non-squamous NSCLC and high-risk genetic alterations

Trial Identifier:	D419MR00003
Sponsor:	AstraZeneca
Start Date:	June 2024
Primary Completion Date:	June 2028
Study Completion Date:	June 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.